玖玖资源网站,爆乳久久久,日韩精品乱码久久久蜜桃,精品呦国产一区二区三区,国产伦高清一区二区三区,sese一区二区,午夜精品福利一区二区三区,三级黄色网站久久免费

首頁
訂購/客服:400-666-5481

GSK2330672

    
99.4%

GSK2330672

源葉(MedMol)
S82917 一鍵復制產品信息
1345982-69-5
C28H38N2O7S
546.6755
Pentanedioic acid, 3-((((3R,5R)-3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,4-benzothiazepin-8-yl)methyl)amino)-; 3-[[(3R,5R)-3-butyl-3-ethyl-7-methoxy-1,1-dioxo-5-phenyl-4,5-d
貨號 規格 價格 上海 北京 武漢 南京 購買數量
S82917-1mg
99.4% ¥800.00 5 - - -
S82917-5mg
99.4% ¥2240.00 6 - - -
S82917-10mg
99.4% ¥3600.00 5 - - -
S82917-50mg
≥99% ¥10400.00 貨期:2-3天 - - -
S82917-100mg
≥99% ¥14400.00 貨期:2-3天 - - -
產品介紹 參考文獻 質檢證書(COA) 摩爾濃度計算器 相關產品

產品介紹

Linerixibat (GSK2330672) is a highly potent, nonabsorbable and orally active apical sodium-dependent bile acid transporter (ASBT) inhibitor with an IC50 of 42 nM human ASBT. Linerixibat can be used as lipid-lowering agent. Linerixibat has the potential for type 2 diabetes and Primary Biliary Cholangitis treatment

產品描述: Linerixibat (GSK2330672) is a highly potent, nonabsorbable and orally active apical sodium-dependent bile acid transporter (ASBT) inhibitor with an IC50 of 42 nM human ASBT. Linerixibat can be used as lipid-lowering agent. Linerixibat has the potential for type 2 diabetes and Primary Biliary Cholangitis treatment
靶點: IC50: 42 nM (Apical sodium-dependent bile acid transporter (ASBT));HBV
體外研究: The zwitterionic, nonhygroscopic, crystalline salt form of Linerixibat (Compound 56) shows good aqueous solubility at pH 7.4 (>7 mg/mL), excellent thermal stability, and did not generate reactive or humanspecific metabolite, characteristics
體內研究: Linerixibat (GSK2330672; 0.05-10 mg/kg; oral gavage; twice daily; for 14 days; male ZDF rat) treatment lowers glucose in an animal model of type 2 diabetes. Animal Model: Male Zucker Diabetic Fatty (ZDF) rat Dosage: 0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg Administration: Oral gavage; twice daily; for 14 days Result: Led to a 1.30-1.64% reduction in hemoglobin A1c (HbA1c), a greater than 50% reduction in nonfasted plasma glucose to below 200 mg/dL, and statistically significant higher plasma insulin.
參考文獻: 1. Wu Y, et al. Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes. J Med Chem. 2013 Jun 27;56(12):5094-114. 2. Wang Y, et al. HNF4α Regulates CSAD to Couple Hepatic Taurine Production to Bile Acid Synthesis in Mice. Gene Expr. 2018 Aug 22;18(3):187-196. 3. Linerixibat (GSK2330672) granted Orphan Status. September 24, 2019.
溶解性: Soluble  in  DMSO
保存條件: -20℃
配置溶液濃度參考:
1mg 5mg 10mg
1 mM 1.829 ml 9.146 ml 18.292 ml
5 mM 0.366 ml 1.829 ml 3.658 ml
10 mM 0.183 ml 0.915 ml 1.829 ml
50 mM 0.037 ml 0.183 ml 0.366 ml
注意: 部分產品我司僅能提供部分信息,我司不保證所提供信息的權威性,僅供客戶參考交流研究之用。

參考文獻

質檢證書(COA)

如何獲取質檢證書(COA)?
請輸入貨號和一個與之匹配的批號。
例如:
批號:JS298415 貨號:S20001-25g
在貨品標簽上如何找到貨號和批號?

摩爾濃度計算器

質量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

=
×
×
主站蜘蛛池模板: 河南省| 尖扎县| 理塘县| 沾化县| 云龙县| 玛沁县| 汶川县| 安康市| 滨州市| 法库县| 铜山县| 屯门区| 襄城县| 香格里拉县| 虞城县| 宝清县| 翁源县| 灵山县| 大埔县| 益阳市| 沈丘县| 南京市| 邮箱| 青铜峡市| 华亭县| 蒙阴县| 称多县| 吉木乃县| 大竹县| 宁南县| 寻乌县| 金塔县| 古蔺县| 丘北县| 寻甸| 盐池县| 济宁市| 栖霞市| 堆龙德庆县| 甘德县| 昌吉市|